1. Pharmacokinetics of ropivacaine in patients with chronic renal failure
P.J. Pere, A. Ekstrand, M. Salonen, E. Honkanen, J. Sjövall, J. Henriksson, P.H. Rosenberg 
British Journal of Anaesthesia 
Volume 106, Issue 4, Pages (April 2011)
DOI: /bja/aer002
Copyright © 2011 The Author(s) Terms and Conditions

2. Fig 1
Total AUC of PPX (best possible estimates) vs CLCR (R2=0.0606, n=28) after i.v. infusion of ropivacaine 1 mg kg−1 in healthy volunteers and in patients with renal impairment.
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

3. Fig 2
1/AUC of PPX (best possible estimates) vs CLR of PPX (Y= X, R2=0.0413, n=28) after i.v. infusion of ropivacaine 1 mg kg−1 in healthy volunteers and in patients with renal impairment.
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

4. Fig 3
Total plasma concentrations of unconjugated 3-OH-ropivacaine after i.v. infusion of ropivacaine 1 mg kg−1 in healthy volunteers (a, CLCR>80 ml min−1), in patients with moderate renal impairment (b, CLCR 25–40 ml min−1), and in patients with severe renal impairment (c, CLCR<25 ml min−1). Number of data points for each patient (median, range): (a) (2, 1–4); (b) (2, 1–4); (c) (3, 2–6).
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

5. Fig 4
Total plasma concentration of PPX after i.v. infusion of ropivacaine hydrochloride 1 mg kg−1 in healthy volunteers (a, CLCR>80 ml min−1), in patients with moderate renal impairment (b, CLCR 25–40 ml min−1), and in patients with severe renal impairment (c, CLCR<25 ml min−1). Number of data points for each patient (median, range): (a) (5, 5–5); b: (5, 4–6); c: (6, 5–6).
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

6. Fig 5
Correlation between CLR of PPX and CLCR after i.v. infusion of ropivacaine 1 mg kg−1 to subjects with and without renal impairment (n=29).
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

7. Fig 6
Correlation between enumerated fraction excreted (fe) as PPX and CLCR (a) (n=29) and between cumulative amount of PPX excreted and CLCR (b) after i.v. infusion of ropivacaine 1 mg kg−1 to subjects with and without renal impairment (n=30).
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

8. Fig 7
Correlation of AUC of PPX and renal clearance for PPX after i.v. infusion of ropivacaine 1 mg kg−1 in healthy volunteers and in patients with renal impairment. Note the two outliers with exceptionally high AUC values.
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions

9. Fig 8
1/AUC of PPX (best possible estimates) vs CLCR (R2=0.0287, n=28) after i.v. infusion of ropivacaine 1 mg kg−1 in healthy volunteers and in patients with renal impairment.
British Journal of Anaesthesia  , DOI: ( /bja/aer002)
Copyright © 2011 The Author(s) Terms and Conditions